Cancer Research CR Mantle 2010 Workshops
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 3317-3320, July 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mollerup, S.
Right arrow Articles by Haugen, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mollerup, S.
Right arrow Articles by Haugen, A.
[Cancer Research 59, 3317-3320, July 15, 1999]
© 1999 American Association for Cancer Research

Advances in Brief

Sex Differences in Lung CYP1A1 Expression and DNA Adduct Levels among Lung Cancer Patients1

Steen Mollerup2, David Ryberg, Allan Hewer, David H. Phillips and Aage Haugen

Department of Toxicology, National Institute of Occupational Health, N-0033 Oslo, Norway [S. M., D. R., Al. H.], and Section of Molecular Carcinogenesis, Institute of Cancer Research, Surrey SM2 5N6, United Kingdom [Aa. H., D. H. P.]


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
Several epidemiological studies have indicated that female tobacco smokers may be at higher risk of lung cancer than males. In a study of lung cancer cases, we have found that female smokers had a significantly higher level of aromatic/hydrophobic DNA adducts in their nontumor lung tissue (15.39 ± 9.47 adducts/108 nucleotides, n = 29) than male smokers (12.08 ± 8.14, n = 93; P = 0.047). Females had significantly higher levels of adducts/pack-year (females 0.95 ± 0.82 adducts/pack-year and males 0.46 ± 0.46; P = 0.0004) and adducts/cigarette/day (females 1.48 ± 1.29 and males 0.89 ± 0.74, P = 0.015). By quantitative reverse transcription-PCR, it was found that female smokers exhibited a significantly higher expression level of lung CYP1A1 (494 ± 334 CYP1A1 mRNA/106 glyceraldehyde-3-phophate dehydrogenase mRNA, n = 15) compared with males (210 ± 208, n = 12; P = 0.016). Furthermore, for both sexes combined a significant correlation between CYP1A1 expression and DNA adduct level was found (r = 0.50, P = 0.009). In conclusion, the observed sex difference in aromatic/hydrophobic DNA adduct levels may at least in part be explained by different levels of CYP1A1 expression.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results
 Discussion
 REFERENCES
 
Lung cancer is the most frequent cancer in the world today, and the epidemic of this disease is still ongoing. Globally, carcinomas of the lung is the most common cause of cancer death, and cigarette smoking is widely accepted as the major risk factor for the incidence of lung cancer (1) . More attention is necessary on the issue of smoking and women because several epidemiological studies indicate that for a given number of cigarettes smoked, females may be at higher risk of lung cancer compared with males (2, 3, 4) . This sex difference may be due to a higher susceptibility to tobacco carcinogens among females.

PAHs3 and nitroso compounds are considered to be carcinogens of major importance in tobacco smoke. The human CYP1A1 gene codes for a central enzyme in the metabolic activation of PAHs, leading to the formation of highly reactive diol-epoxides that may bind to DNA. Smoking-related DNA adducts in lung tissue may be a molecular exposure marker (5 , 6) . DNA adduct levels have been shown to correlate with the level of AHH activity (7) , which again correlates with the level of CYP1A1 mRNA (8) . A good correlation between the carcinogenic potency and DNA adduct formation ability has been observed experimentally for several carcinogens, including PAHs (for review, see Ref. 9 ). In humans, some studies have indicated that the level of hydrophobic DNA adducts may be a risk factor for the development of lung cancer (5 , 6 , 10) . In addition, among lung cancer patients, high levels of lung DNA adducts have been related to an early onset of the disease (11) .

CYP1A1 expression is induced by PAHs and halogenated aromatic hydrocarbons. In human lung tissue, CYP1A1 expression is inducible by cigarette smoking (8) . Both a high degree of interindividual variability in CYP1A1 inducibility, and a correlation between level of inducibility in human lymphocytes and risk of lung cancer have been demonstrated in smokers (12) . It seems that induction of CYP1A1 expression is controlled primarily at the level of transcription.

We have reported previously (11 , 13) a higher level of lung hydrophobic DNA adducts and a higher frequency of G:C->T:A transversions in the p53 gene in the lung tumors of smoking female lung cancer patients, which lends support to the hypothesis that females are at increased risk of developing smoke-induced lung cancer. To clarify this sex dependence of PAH-induced DNA adducts further, we have determined the levels of hydrophobic DNA adducts in nontumor lung tissue of lung cancer patients in the present, extended study. Furthermore, we have used quantitative competitive RT-PCR to study expression of the CYP1A1 gene in the lung tissue of currently smoking patients.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results
 Discussion
 REFERENCES
 
Study Population.
Samples of normal lung tissue adjacent to tumor tissue were resected at the time of surgery of 159 previously untreated lung cancer patients. The tissue was snap-frozen and stored at - 80°C. Demographic patient data on sex, age, and smoking history (see Table 1Citation ) were obtained by questionnaires as described previously (11) . Hydrophobic DNA adduct levels were measured in 29 female and 93 male smokers as well as 13 female and 24 male nonsmokers (never-smokers and ex-smokers of 2 or more years of abstinence). CYP1A1 gene expression was studied in a subset consisting of 15 female and 12 male current smokers: mean age ± SD was 55 ± 13 years (females) and 60 ± 11 years (males; nonsignificant); smoking history was 12.2 ± 5.2 cigarettes/day (females) and 15.8 ± 7.1 cigarettes/day (males; nonsignificant); and pack-years was 20 ± 9 (females) and 30 ± 16 (males; P = 0.04).


View this table:
[in this window]
[in a new window]

  		Table 1 Lung hydrophobic DNA adducts, smoking history, and age of female and male lung cancer patients

 
Quantitative RT-PCR.
Gene expression was determined using quantitative competitive RT-PCR modified from Celi et al. (14) and Willey et al. (15) . In brief, CYP1A1 and GAPDH cDNA (native) was amplified in the presence of known amounts of synthetic CTs derived from the respective cDNA sequences. The CTs give rise to PCR products that are identical to the native cDNA sequence apart from a deletion and will be amplified by the native primers. In each case, cDNA was titrated against the corresponding CT to determine the amount needed to result in equal levels of PCR products.

Total RNA was extracted from frozen nontumor lung tissue by the TRIzol reagent (Life Technologies, Inc., Rockville, MD) following the supplier’s protocol. mRNA was reversibly transcribed by aid of the 1st Strand cDNA Synthesis kit for RT-PCR (1st Strand cDNA Synthesis Kit for RT-PCR [AMV], Boehringer Mannheim, Mannheim, Germany), using oligo-p(dT)15 primers. Primer sequences for quantitative competitive PCR CYP1A1 were: (a) CYP1A1 native upper 5'-CAT CCC CCA CAG CAC AAC AAG-3'; (b) CYP1A1 native lower 5'-AGA GCA GGC ATG CTT CAT GGT-3'; and (c) CYP1A1 CT lower 5'-AGA GCA GGC ATG CTT CAT GGT TCT CAC CGA TAC ACT TCC GCT-3' (15) . These primers give rise to PCR-products of 355 bp (native) and 248 bp (CT). GAPDH primer sequences were: (a) GAPDH native upper 5'-ACA GTC CAT GCC ATC ACT GCC-3'; (b) GAPDH native lower 5'-GCC TGC TTC ACC ACC TTC TTG; and (c) GAPDH CT upper 5'-ACA GTC CAT GCC ATC ACT GCC ATC ATC CCT GCC TCT ACT GGC-3'. PCR products for GAPDH were 266 bp (native) and 200 bp (CT). The cDNA sequence for GAPDH was from the GenBank, and primer sequences were chosen using the Oligo software (National Biosciences, Plymouth, MN). For the PCR reactions, the DynaZyme II Thermostable recombinant DNA polymerase from Finnzymes Oy (Espoo, Finland) was used together with the supplier’s buffer conditions. Because of differences in mRNA levels of several orders of magnitude, CYP1A1 and GAPDH were amplified in separate reactions for 30 and 20 cycles, respectively, of 94°C for 20 s, 58°C for 30 s, and 72°C for 60 s]. PCR products were electrophoresed on 6.7% polyacrylamide gels (29:1), visualized by the SYBR Green I nucleic acid gel stain (FMC BioProducts, Rockland, ME), and photographed with a CCD camera. Levels of PCR products were measured by densitometric analysis of gel images using the public domain NIH Image program. All of the RT-PCR experiments were repeated at least three times with similar results.

Aromatic/Hydrophobic DNA Adducts.
DNA was extracted from nontumor lung tissue and aromatic/hydrophobic DNA adducts were measured by 32P postlabeling analysis with the nuclease P1 modification as described previously (16) .

Statistical Analysis.
Student’s t test and the Wilcoxon signed rank test were used for the comparison of means. Association between the levels of CYP1A1 expression and hydrophobic DNA adducts was determined by linear regression analysis. Fitness to the linear regression model was ascertained by the examination of both a normal probability plot of the data points and residual values.


   Results
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
Discussion
 REFERENCES
 
In a pilot study, we have previously shown that female lung cancer patients have higher levels of DNA adducts in their normal lung tissue than males, when adjusted for smoking dose (11) . In the present study, the levels of hydrophobic/aromatic DNA adducts were measured in lung tissue from 159 lung cancer patients by 32P postlabeling with the nuclease P1 modification. As shown in Table 1Citation , the levels of DNA adducts were highly significantly increased among both smoking females and smoking males compared with nonsmokers (P = 3 x 10-7 and P = 4 x 10-8, respectively). Significantly higher levels of DNA adducts were found among female smokers compared with male smokers (P = 0.047) although the latter had smoked more, verifying our previously published data (11) . When expressing DNA adduct levels in relation to smoking dose, we found that levels of adducts/pack-year (females, 0.95 ± 0.82, and males, 0.46 ± 0.46) and adducts/cigarette/day (females, 1.48 ± 1.29, and males, 0.89 ± 0.74) were significantly higher among females (P = 0.0004 and P = 0.015, respectively).

The expression of the CYP1A1 gene was determined in normal lung tissue from a subset consisting of currently smoking lung cancer patients. CYP1A1 expression was normalized to the expression of GAPDH by quantitative competitive RT-PCR as described in "Materials and Methods" (Fig. 1)Citation . Large interindividual variations were observed with a total range of 21–1122 CYP1A1 mRNA/106 GAPDH mRNA. When grouped by sex, a significantly higher mean CYP1A1 expression was found for females than for males (P = 0.016; Fig. 2)Citation .



View larger version (66K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. A representative case of quantitative competitive RT-PCR measurement of (A) CYP1A1 and (B) GAPDH gene expression. RT-PCR was carried out as described in "Materials and Methods." Arrows, PCR products originating from native cDNAs and CTs. The amount of template added in each PCR reaction is indicated on the figure (µl of cDNA and copies of CT, respectively). Gene expression was determined by densitometric scanning of digital images of the electrophoresis gels. M, PhiX174 RF DNA, HaeIII-digested molecular weight marker (bands of 310, 281, 271, 234, and 194 bp are shown).

 


View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Box plots of pulmonary CYP1A1 expression among currently smoking lung cancer patients grouped by sex. CYP1A1 mRNA expression (normalized to the expression of GAPDH) of individual cases was determined by densitometric analysis of quantitative competitive RT-PCR gels such as those presented in Fig. 1Citation . Mean ± SD CYP1A1 expression was 494 ± 334 CYP1A1/106 GAPDH (95% confidence interval, 310–679; n = 15) for females and 210 ± 208 CYP1A1/106 GAPDH (95% confidence interval, 78–342; n = 12) for males (P = 0.016, Student’s t test).

 
Linear regression analysis revealed that the hydrophobic DNA adduct levels were significantly related to the level of CYP1A1 expression (with the exclusion of one outlier), r = 0.50, P = 0.009 (Fig. 3)Citation . The excluded data point from the linear regression analysis was found to be an outlier in a normal probability plot, as well as having a twice as high residual value as the data point with the second largest value. No correlation was found between CYP1A1 expression and either number of cigarettes smoked per day or age of the patients.



View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Correlation between CYP1A1 expression and hydrophobic DNA adducts. Individual measurements of hydrophobic DNA adduct levels were plotted against CYP1A1 mRNA expression (normalized to the expression of GAPDH) for both sexes combined. One outlier ({circ}) was excluded from the analysis. Linear regression line is shown on the plot: n = 26, r = 0.50, P = 0.009.

 

   Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
REFERENCES
 
The formation of hydrophobic/aromatic DNA adducts in the lung is induced by PAH present in tobacco smoke. The metabolism of PAH is complex, including an activation reaction (Phase I) that involves members of the cytochrome P450 monooxygenases and a detoxifying conjugation reaction via the various Phase II enzymes. Several previous studies have shown significantly higher DNA adduct levels in smokers compared with nonsmokers (5 , 6 , 10) . Among smokers, our data showed that PAH-DNA adduct levels were inversely related to age, years of smoking, or pack-years. Years of smoking was the most significant single smoking-related parameter explaining the variation in adduct levels. Thus, it may be interpreted that some individuals are predisposed to high adduct levels without regard to the daily smoking dose. These individuals will statistically have an earlier onset of lung cancer than individuals with low adduct levels. In our study, females had significantly higher PAH-adduct levels than males and an earlier onset of the disease (lower mean age at the time of diagnosis). This indicates that females are more susceptible to PAH exposure than males, which confirms our previous results (11) .

AHH has been found to correlate with CYP1A1 mRNA (Ref. 8 and unpublished data).4 In human lung tissue both CYP1A1 mRNA and AHH activity are induced by PAHs present in tobacco smoke (8 , 17) . To evaluate the role of AHH activity in the observed sex difference in smoke-induced DNA adducts, CYP1A1 gene expression was measured in currently smoking lung cancer patients. We found that females had significantly higher levels of CYP1A1 expression in their nontumor lung tissue than males. Because it has been reported that CYP1A1 gene expression is reduced as early as 2 weeks after smoking cessation (8) , only patients who were smoking up to the time of surgery were included in the CYP1A1 expression study.

We have used a highly reliable quantitative competitive RT-PCR method to study CYP1A1 expression, relating the CYP1A1 gene transcript to the expression of the GAPDH gene. Both cDNAs were amplified in the presence of CTs that were identical to the particular cDNA sequence apart from a deletion. Titration of the cDNA against known amounts of the respective template allowed accurate quantification of the expression. Because of a high degree of sequence homology between the genes for CYP1A1 and CYP1A2, the PCR primers for CYP1A1 cDNA amplification will also amplify CYP1A2 cDNA, which results in PCR products that are indistinguishable upon gel electrophoresis. However, CYP1A2 has been reported not to be expressed in human lung (18) . In addition, similar to the results reported in the present study, a significantly higher expression level of pulmonary CYP1A1 among smoking female lung cancer patients was found by using semiquantitative RT-PCR and primers that were specific for CYP1A1 only (19) .

Hydrophobic DNA adduct levels were found to be significantly related to the level of CYP1A1 expression, although a large interindividual variation was observed for both DNA adducts and CYP1A1 expression. In agreement with our data, a significant correlation has been demonstrated between AHH activity and DNA adducts in nontumor lung tissue of smoking lung cancer patients (20) . Considering the rapid turnover of CYP1A1 mRNA, and a half-life of 1.7 years for DNA adducts in bronchial tissue from ex-smokers (6 , 8) , we found a correlation coefficient (r) of 0.50, which means that 25% of the variation in the level of DNA adducts could be explained by the variation in CYP1A1 expression. Clearly, the level of DNA adducts is influenced by factors other than CYP1A1, such as exposure to PAH, Phase II metabolism, DNA repair processes, and cell turnover.

Several, although not all, epidemiological studies indicate that females may be at greater risk of developing lung cancer than males (2, 3, 4) . In addition to higher levels of smoking-induced CYP1A1 gene expression and higher levels of DNA adducts among female lung cancer patients, women seem to have higher frequencies of G:C->T:A base substitution mutations in the p53 gene (11 , 13 , 21) . Together, these data provide evidence for sex differences in lung cancer susceptibility at the genetic and biochemical level. The mechanism(s) is unknown, but the hypothesis of a possible role of hormones has been put forward (22) . In vitro studies have suggested complex interactions between the ER and the aryl hydrocarbon receptor pathways (23) . It is possible that circulating female steroid hormones(s) may interact with receptors present in the lung and modulate the expression of PAH metabolizing enzymes. Sex-steroid-receptor expression has been found to be more frequent in lung tumors from female than from male patients (24) . Expression of ER-{alpha}, as detected by immunocytochemistry, is infrequent in normal lung. Little is known about the expression of the recently cloned ER-ß in adult human lung, but this receptor subtype has been demonstrated to be frequently expressed in rat lung tissue as well as in fetal human lung (25 , 26) .


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This study was supported by the Norwegian Cancer Society and the United Kingdom Cancer Research Campaign. Back

2 To whom requests for reprints should be addressed, at Department of Toxicology, National Institute of Occupational Health, P. O. Box 8149 Dep, N-0033 Oslo, Norway. E-mail: Steen.Mollerup{at}stami.no Back

3 The abbreviations used are: PAH, polycyclic aromatic hydrocarbon; CYP1A1, cytochrome P4501A1; AHH, aromatic hydrocarbon hydroxylase; RT-PCR, reverse transcription-PCR; GAPDH, glyceraldehyde-3-phophate dehydrogenase; CT, competitive template; ER, estrogen receptor. Back

4 Unpublished data. Back

Received 2/ 5/99. Accepted 6/ 1/99.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 

  1. Peto R., Lopez A. D., Boreham J., Thun M., Heath C., Jr., Doll R. Mortality from smoking worldwide. Br. Med. Bull., 52: 12-21, 1996.[Abstract/Free Full Text]
  2. Engeland A. Trends in the incidence of smoking-associated cancers in Norway, 1954-93. Int. J. Cancer, 68: 39-46, 1996.[Medline]
  3. Zang E. A., Wynder E. L. Differences in lung cancer risk between men and women: examination of the evidence. J. Natl. Cancer Inst., 88: 183-192, 1996.
  4. Prescott E., Osler M., Hein H. O., Borch-Jonsen K., Lange P., Schnohr P., Vestbo J. Gender and smoking-related risk of lung cancer: The Copenhagen Center for Prospective Population Studies. Epidemiology, 9: 79-83, 1998.[Medline]
  5. Phillips D. H., Hewer A., Martin C. N., Garner R. C., King M. M. Correlation of DNA adduct levels in human lung with cigarette smoking. Nature (Lond.), 336: 790-792, 1988.[Medline]
  6. Schoket B., Phillips D. H., Kostic S., Vincze I. Smoking-associated bulky DNA adducts in bronchial tissue related to CYP1A1 MspI and GSTM1 genotypes in lung patients. Carcinogenesis (Lond.), 19: 841-846, 1998.[Abstract/Free Full Text]
  7. Alexandrov K., Rojas M., Geneste O., Castegnaro M., Camus A. M., Petruzzelli S., Giuntini C., Bartsch H. An improved fluorometric assay for dosimetry of benzo(a)pyrene diol-epoxide-DNA adducts in smokers’ lung: comparisons with total bulky adducts and aryl hydrocarbon hydroxylase activity. Cancer Res., 52: 6248-6253, 1992.[Abstract/Free Full Text]
  8. McLemore T. L., Adelberg S., Liu M. C., McMahon N. A., Yu S. J., Hubbard W. C., Czerwinski M., Wood T. G., Storeng R., Lubet R. A., Eggleston J. C., Boyd M. R., Hines R. N. Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J. Natl. Cancer Inst., 82: 1333-1339, 1990.[Abstract/Free Full Text]
  9. Kriek E., Rojas M., Alexandrov K., Bartsch H. Polycyclic aromatic hydrocarbon-DNA adducts in humans: relevance as biomarkers for exposure and cancer risk. Mutat. Res., 400: 215-231, 1998.[Medline]
  10. Tang D., Santella R. M., Blackwood A. M., Young T-L., Mayer J., Jaretzki A., Grantham S., Tsai W-Y., Perera F. P. A molecular epidemiological case-control study of lung cancer. Cancer Epidemiol. Biomark. Prev., 4: 341-346, 1995.[Abstract]
  11. Ryberg D., Hewer A., Phillips D. H., Haugen A. Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients. Cancer Res., 54: 5801-5803, 1994.[Abstract/Free Full Text]
  12. Stücker I., Kremers P., Jacquet M., Genee S., de Waziers I., Beaune P., Hemon D. CYP1A1 inducibility, GSTM1, smoking and lung cancer. Results of a French case control study. Proc. Am. Assoc. Cancer Res., 39: 627 1998.
  13. Kure E. H., Ryberg D., Hewer A., Phillips D. H., Skaug V., Bæra R., Haugen A. p53 mutations in lung tumors: relationship to gender and lung DNA adduct levels. Carcinogenesis (Lond.), 17: 2201-2205, 1996.[Abstract/Free Full Text]
  14. Celi F. S., Zenilman M. E., Shuldiner A. R. A rapid and versatile method to synthesize internal standards for competitive PCR. Nucleic Acids Res., 21: 1047 1993.[Free Full Text]
  15. Willey J. C., Coy E. L., Frampton M. W., Torres A., Apostolakos M. J., Hoehm G., Schuermann W. H., Thilly W. G., Olson D. E., Hammersley J. R., Crespi C. L., Utell M. J. Quantitative RT-PCR measurement of cytochrome P450 1A1, 1B1, and 2B7, microsomal epoxide hydroxylase, and NADPH oxidoreductase expression in lung cells of smokers and nonsmokers. Am. J. Respir. Cell Mol. Biol., 17: 114-124, 1997.[Abstract/Free Full Text]
  16. Phillips D. H., Schoket B., Hewer A., Bailey E., Kostic S., Vincze I. Influence of cigarette smoking on the level of DNA adducts in human bronchial epithelium and white blood cells. Int. J. Cancer, 46: 569-575, 1990.[Medline]
  17. Antilla S., Hietanen E., Vainio H., Camus A.-M., Gelboin H. V., Park S. S., Heikkilä L., Karjalainen A., Bartsch H. Smoking and peripheral type of cancer are related to high levels of pulmonary cytochrome P450IA in lung cancer patients. Int. J. Cancer, 47: 681-685, 1991.[Medline]
  18. Raunio H., Hakkola J., Hukkanen J., Pelkonen O., Edwards R., Boobis A., Anttila S. Expression of xenobiotic-metabolizing cytochrome P450s in human pulmonary tissues. Arch. Toxicol. Suppl., 20: 465-469, 1998.[Medline]
  19. Mollerup S., Ryberg D., Hewer A., Phillips D. H., Skaug V., Haugen A. Gender differences in CYP1A1 expression among lung cancer patients. Proc. Am. Assoc. Cancer Res., 39: 337 1998.
  20. Geneste O., Camus A-M., Castegnaro M., Petruzzelli S., Macchiarini P., Angeletti C. A., Giuntini C., Bartsch H. Comparison of pulmonary DNA adduct levels, measured by 32P-postlabeling and aryl hydrocarbon hydroxylase activity in lung parenchyma of smokers and ex-smokers. Carcinogenesis (Lond.), 12: 1301-1305, 1991.[Abstract/Free Full Text]
  21. Guinee D. G., Jr., Travis W. D., Trivers G. E., De Benedetti V. M. G., Cawley H., Welsh J. A., Bennett W. P., Jett J., Colby T. V., Tazelaar H., Abbondanzo S. L., Pairolero P., Trastek V., Caparaso N. E., Liotta L. A., Harris C. C. Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 antibodies and C-erbB-2 expression. Carcinogenesis (Lond.), 16: 993-1002, 1995.[Abstract/Free Full Text]
  22. Taioli E., Wynder E. L. Re: endocrine factors and adenocarcinoma of the lung in women. J. Natl. Cancer Inst., 86: 869-870, 1994.[Free Full Text]
  23. Thomsen J. S., Wang X., Hines R. N., Safe S. Restoration of aryl hydrocarbon (Ah) responsiveness in MDA-MB-231 human breast cancer cells by transient expression of the estrogen receptor. Carcinogenesis (Lond.), 15: 933-937, 1994.[Abstract/Free Full Text]
  24. Kaiser U., Hofmann J., Schilli M., Wegmann B., Klotz U., Wedel S., Virmani A. K., Wollmer E., Branscheid D., Gazdar A. F., Havemann K. Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. Int. J. Cancer, 67: 357-364, 1996.[Medline]
  25. Brandenberger A. W., Tee M. K., Lee J. Y., Chao V., Jaffe R. B. Tissue distribution of estrogen receptor {alpha} (ER-{alpha}) and ß (ER-ß) mRNA in the midgestational human fetus. J. Clin. Endocrinol. & Metab., 82: 3509-3512, 1997.[Abstract/Free Full Text]
  26. Kuiper G. G., Carlsson B., Grandien K., Enmark E., Haggblad J., Nilsson S., Gustafsson J. A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptor {alpha} and ß. Endocrinology, 138: 863-870, 1997.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 CarcinogenesisHome page
S. Zienolddiny, V. Skaug, N. E. Landvik, D. Ryberg, D. H. Phillips, R. Houlston, and A. Haugen
The TERT-CLPTM1L lung cancer susceptibility variant associates with higher DNA adduct formation in the lung
Carcinogenesis, August 1, 2009; 30(8): 1368 - 1371.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
C. Penaloza, B. Estevez, S. Orlanski, M. Sikorska, R. Walker, C. Smith, B. Smith, R. A. Lockshin, and Z. Zakeri
Sex of the cell dictates its response: differential gene expression and sensitivity to cell death inducing stress in male and female cells
FASEB J, June 1, 2009; 23(6): 1869 - 1879.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M. L. Cote, W. Yoo, A. S. Wenzlaff, G. M. Prysak, S. K. Santer, G. B. Claeys, A. L. Van Dyke, S. J. Land, and A. G. Schwartz
Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in women
Carcinogenesis, April 1, 2009; 30(4): 626 - 635.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
R. Singhal, K. Shankar, T. M. Badger, and M. J. Ronis
Estrogenic status modulates aryl hydrocarbon receptor--mediated hepatic gene expression and carcinogenicity
Carcinogenesis, February 1, 2008; 29(2): 227 - 236.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. G. Schwartz, A. S. Wenzlaff, G. M. Prysak, V. Murphy, M. L. Cote, S. C. Brooks, D. F. Skafar, and F. Lonardo
Reproductive Factors, Hormone Use, Estrogen Receptor Expression and Risk of Non Small-Cell Lung Cancer in Women
J. Clin. Oncol., December 20, 2007; 25(36): 5785 - 5792.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
D. D. Sin, S. B.-Z. Cohen, A. Day, H. Coxson, and P. D. Pare
Understanding the Biological Differences in Susceptibility to Chronic Obstructive Pulmonary Disease between Men and Women
Proceedings of the ATS, December 1, 2007; 4(8): 671 - 674.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
C. M. Tammemagi, M. T. Freedman, T. R. Church, M. M. Oken, W. G. Hocking, P. A. Kvale, P. Hu, T. L. Riley, L. R. Ragard, P. C. Prorok, et al.
Factors Associated with Human Small Aggressive Non Small Cell Lung Cancer
Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 2082 - 2089.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Jiang, J.-M. Yuan, P. L. Skipper, S. R. Tannenbaum, and M. C. Yu
Environmental Tobacco Smoke and Bladder Cancer Risk in Never Smokers of Los Angeles County
Cancer Res., August 1, 2007; 67(15): 7540 - 7545.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. Ben-Zaken Cohen, P. D. Pare, S. F. P. Man, and D. D. Sin
The Growing Burden of Chronic Obstructive Pulmonary Disease and Lung Cancer in Women: Examining Sex Differences in Cigarette Smoke Metabolism
Am. J. Respir. Crit. Care Med., July 15, 2007; 176(2): 113 - 120.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. P. Wisnivesky and E. A. Halm
Sex Differences in Lung Cancer Survival: Do Tumors Behave Differently in Elderly Women?
J. Clin. Oncol., May 1, 2007; 25(13): 1705 - 1712.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
C. J. Gallagher, J. E. Muscat, A. N. Hicks, Y. Zheng, A.-M. Dyer, G. A. Chase, J. Richie, and P. Lazarus
The UDP-Glucuronosyltransferase 2B17 Gene Deletion Polymorphism: Sex-Specific Association with Urinary 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol Glucuronidation Phenotype and Risk for Lung Cancer
Cancer Epidemiol. Biomarkers Prev., April 1, 2007; 16(4): 823 - 828.
[Abstract] [Full Text] [PDF]

Home page
 MutagenesisHome page
D. Mielzynska, E. Siwinska, L. Kapka, K. Szyfter, L. E. Knudsen, and D. F. Merlo
The influence of environmental exposure to complex mixtures including PAHs and lead on genotoxic effects in children living in Upper Silesia, Poland
Mutagenesis, September 1, 2006; 21(5): 295 - 304.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
S. M Dougherty, W. Mazhawidza, A. R Bohn, K. A Robinson, K. A Mattingly, K. A Blankenship, M. O Huff, W. G McGregor, and C. M Klinge
Gender difference in the activity but not expression of estrogen receptors {alpha} and {beta} in human lung adenocarcinoma cells.
Endocr. Relat. Cancer, March 1, 2006; 13(1): 113 - 134.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
S. Zienolddiny, D. Campa, H. Lind, D. Ryberg, V. Skaug, L. Stangeland, D. H. Phillips, F. Canzian, and A. Haugen
Polymorphisms of DNA repair genes and risk of non-small cell lung cancer
Carcinogenesis, March 1, 2006; 27(3): 560 - 567.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. G. Schwartz, G. M. Prysak, V. Murphy, F. Lonardo, H. Pass, J. Schwartz, and S. Brooks
Nuclear Estrogen Receptor {beta} in Lung Cancer: Expression and Survival Differences by Sex
Clin. Cancer Res., October 15, 2005; 11(20): 7280 - 7287.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
L. Airoldi, P. Vineis, A. Colombi, L. Olgiati, C. Dell'Osta, R. Fanelli, L. Manzi, F. Veglia, H. Autrup, A. Dunning, et al.
4-Aminobiphenyl-Hemoglobin Adducts and Risk of Smoking-Related Disease in Never Smokers and Former Smokers in the European Prospective Investigation into Cancer and Nutrition Prospective Study
Cancer Epidemiol. Biomarkers Prev., September 1, 2005; 14(9): 2118 - 2124.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
L. Thomas, L. A. Doyle, and M. J. Edelman
Lung Cancer in Women: Emerging Differences in Epidemiology, Biology, and Therapy
Chest, July 1, 2005; 128(1): 370 - 381.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
S Wasswa-Kintu, W Q Gan, S F P Man, P D Pare, and D D Sin
Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis
Thorax, July 1, 2005; 60(7): 570 - 575.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
Q. Shi, Z. Zhang, G. Li, P. C. Pillow, L. M. Hernandez, M. R. Spitz, and Q. Wei
Sex Differences in Risk of Lung Cancer Associated with Methylene-tetrahydrofolate Reductase Polymorphisms
Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1477 - 1484.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. D. Patel
Lung Cancer in Women
J. Clin. Oncol., May 10, 2005; 23(14): 3212 - 3218.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
M. B. Schabath, G. L. Delclos, H. B. Grossman, Y. Wang, S. P. Lerner, R. M. Chamberlain, M. R. Spitz, and X. Wu
Polymorphisms in XPD Exons 10 and 23 and Bladder Cancer Risk
Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 878 - 884.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
A. J. Marrogi, L. E. Mechanic, J. A. Welsh, E. D. Bowman, M. A. Khan, L. Enewold, P. G. Shields, and C. C. Harris
TP53 Mutation Spectrum in Lung Cancer Is Not Different in Women and Men
Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 1031 - 1033.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. J. Barnes
The Changing Face of Lung Cancer
Chest, December 1, 2004; 126(6): 1718 - 1721.
[Full Text] [PDF]

Home page
 Toxicol PatholHome page
Aspen Cancer Conference Fellows
Toxicol Pathol, October 1, 2004; 32(6): 749 - 761.
[PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
J. Olak and Y. Colson
Gender differences in lung cancer: Have we really come a long way, baby?
J. Thorac. Cardiovasc. Surg., September 1, 2004; 128(3): 346 - 351.
[Full Text] [PDF]

Home page
 JAMAHome page
J. D. Patel, P. B. Bach, and M. G. Kris
Lung Cancer in US Women: A Contemporary Epidemic
JAMA, April 14, 2004; 291(14): 1763 - 1768.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. D. Spivack, G. J. Hurteau, M. J. Fasco, and L. S. Kaminsky
Phase I and II Carcinogen Metabolism Gene Expression in Human Lung Tissue and Tumors
Clin. Cancer Res., December 1, 2003; 9(16): 6002 - 6011.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
K. A. Warner, E. L. Crawford, A. Zaher, R. J. Coombs, H. Elsamaloty, S. L. Roshong-Denk, I. Sharief, G. V. Amurao, Y. Yoon, A. Y. Al-Astal, et al.
The c-myc x E2F-1/p21 Interactive Gene Expression Index Augments Cytomorphologic Diagnosis of Lung Cancer in Fine-Needle Aspirate Specimens
J. Mol. Diagn., August 1, 2003; 5(3): 176 - 183.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
T. K. H. Chang, J. Chen, V. Pillay, J.-Y. Ho, and S. M. Bandiera
Real-Time Polymerase Chain Reaction Analysis of CYP1B1 Gene Expression in Human Liver
Toxicol. Sci., January 1, 2003; 71(1): 11 - 19.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
P. Lin, S.-W. Hu, and T.-H. Chang
Correlation between Gene Expression of Aryl Hydrocarbon Receptor (AhR), Hydrocarbon Receptor Nuclear Translocator (Arnt), Cytochromes P4501A1 (CYP1A1) and 1B1 (CYP1B1), and Inducibility of CYP1A1 and CYP1B1 in Human Lymphocytes
Toxicol. Sci., January 1, 2003; 71(1): 20 - 26.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
K. Alexandrov, I. Cascorbi, M. Rojas, G. Bouvier, E. Kriek, and H. Bartsch
CYP1A1 and GSTM1 genotypes affect benzo[a]pyrene DNA adducts in smokers' lung: comparison with aromatic/hydrophobic adduct formation
Carcinogenesis, December 1, 2002; 23(12): 1969 - 1977.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
D. H. Phillips
Smoking-related DNA and protein adducts in human tissues
Carcinogenesis, December 1, 2002; 23(12): 1979 - 2004.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Harada, S. Toyooka, N. Shivapurkar, A. Maitra, J. L. Reddy, H. Matta, K. Miyajima, C. F. Timmons, G. E. Tomlinson, D. Mastrangelo, et al.
Deregulation of Caspase 8 and 10 Expression in Pediatric Tumors and Cell Lines
Cancer Res., October 15, 2002; 62(20): 5897 - 5901.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
F. P. Perera, L. A. Mooney, M. Stampfer, D. H. Phillips, D. A. Bell, A. Rundle, S. Cho, W.-Y. Tsai, J. Ma, A. Blackwood, et al.
Associations between carcinogen-DNA damage, glutathione S-transferase genotypes, and risk of lung cancer in the prospective Physicians' Health Cohort Study
Carcinogenesis, October 1, 2002; 23(10): 1641 - 1646.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Banerjee, C. Bueso-Ramos, and B. B. Aggarwal
Suppression of 7,12-Dimethylbenz(a)anthracene-induced Mammary Carcinogenesis in Rats by Resveratrol: Role of Nuclear Factor-{kappa}B, Cyclooxygenase 2, and Matrix Metalloprotease 9
Cancer Res., September 1, 2002; 62(17): 4945 - 4954.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. P. Stabile, A. L. G. Davis, C. T. Gubish, T. M. Hopkins, J. D. Luketich, N. Christie, S. Finkelstein, and J. M. Siegfried
Human Non-Small Cell Lung Tumors and Cells Derived from Normal Lung Express Both Estrogen Receptor {alpha} and {beta} and Show Biological Responses to Estrogen
Cancer Res., April 1, 2002; 62(7): 2141 - 2150.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A. Haugen
Women who smoke: are women more susceptible to tobacco-induced lung cancer?
Carcinogenesis, February 1, 2002; 23(2): 227 - 229.
[Full Text] [PDF]

Home page
 ChestHome page
S. A. Khuder and A. B. Mutgi
Effect of Smoking Cessation on Major Histologic Types of Lung Cancer
Chest, November 1, 2001; 120(5): 1577 - 1583.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
P. Georgiadis, J. Topinka, M. Stoikidou, S. Kaila, M. Gioka, K. Katsouyanni, R. Sram, H. Autrup, and S. A. Kyrtopoulos
Biomarkers of genotoxicity of air pollution (the AULIS project): bulky DNA adducts in subjects with moderate to low exposures to airborne polycyclic aromatic hydrocarbons and their relationship to environmental tobacco smoke and other parameters
Carcinogenesis, September 1, 2001; 22(9): 1447 - 1457.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Tang, D. H. Phillips, M. Stampfer, L. A. Mooney, Y. Hsu, S. Cho, W.-Y. Tsai, J. Ma, K. J. Cole, M. N. She, et al.
Association between Carcinogen-DNA Adducts in White Blood Cells and Lung Cancer Risk in the Physicians Health Study
Cancer Res., September 1, 2001; 61(18): 6708 - 6712.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
G. B. J. Smith, P. A. Harper, J. M. Y. Wong, M. S. M. Lam, K. R. Reid, D. Petsikas, and T. E. Massey
Human Lung Microsomal Cytochrome P4501A1 (CYP1A1) Activities: Impact of Smoking Status and CYP1A1, Aryl Hydrocarbon Receptor, and Glutathione S-Transferase M1 Genetic Polymorphisms
Cancer Epidemiol. Biomarkers Prev., August 1, 2001; 10(8): 839 - 853.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
R. S. Obach
Cytochrome P450-Catalyzed Metabolism of Ezlopitant Alkene (CJ-12,458), a Pharmacologically Active Metabolite of Ezlopitant: Enzyme Kinetics and Mechanism Of an Alkene Hydration Reaction
Drug Metab. Dispos., July 1, 2001; 29(7): 1057 - 1067.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. O. Toyooka, S. Toyooka, A. K. Virmani, U. G. Sathyanarayana, D. M. Euhus, M. Gilcrease, J. D. Minna, and A. F. Gazdar
Loss of Expression and Aberrant Methylation of the CDH13 (H-Cadherin) Gene in Breast and Lung Carcinomas
Cancer Res., June 1, 2001; 61(11): 4556 - 4560.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. E. Castelao, J.-M. Yuan, P. L. Skipper, S. R. Tannenbaum, M. Gago-Dominguez, J. S. Crowder, R. K. Ross, and M. C. Yu
Gender- and Smoking-Related Bladder Cancer Risk
J Natl Cancer Inst, April 4, 2001; 93(7): 538 - 545.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
J.A. Williams
Single nucleotide polymorphisms, metabolic activation and environmental carcinogenesis: why molecular epidemiologists should think about enzyme expression
Carcinogenesis, February 1, 2001; 22(2): 209 - 214.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
R. Goth-Goldstein, M. R. Stampfer, C. A. Erdmann, and M. Russell
Interindividual variation in CYP1A1 expression in breast tissue and the role of genetic polymorphism
Carcinogenesis, November 1, 2000; 21(11): 2119 - 2122.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
J. W. Lampe, I. B. King, S. Li, M. T. Grate, K. V. Barale, C. Chen, Z. Feng, and J. D. Potter
Brassica vegetables increase and apiaceous vegetables decrease cytochrome P450 1A2 activity in humans: changes in caffeine metabolite ratios in response to controlled vegetable diets
Carcinogenesis, June 1, 2000; 21(6): 1157 - 1162.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
F. P. Perera
Molecular Epidemiology: On the Path to Prevention?
J Natl Cancer Inst, April 19, 2000; 92(8): 602 - 612.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
H. Bartsch, U. Nair, A. Risch, M. Rojas, H. Wikman, and K. Alexandrov
Genetic Polymorphism of CYP Genes, Alone or in Combination, as a Risk Modifier of Tobacco-related Cancers
Cancer Epidemiol. Biomarkers Prev., January 1, 2000; 9(1): 3 - 28.
[Abstract] [Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mollerup, S.
Right arrow Articles by Haugen, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mollerup, S.
Right arrow Articles by Haugen, A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online